#Probiotic #Inflammation #GutMicrobiota
#ChronicDisease #GutHealth
Non-communicable diseases (NCDs) such as type 2
diabetes, multiple sclerosis, cardiovascular disorders, and neurodegenerative
diseases are now the leading causes of chronic illness and mortality worldwide.
These persistent conditions are often associated with an unfavorable
biological
background marked by
low-grade inflammation and
sustained oxidative stress.
Both mechanisms are now recognized as key drivers in the progression of NCDs,
promoting
metabolic dysregulation, cellular damage, and
gradual loss of physiological
function.
In this context,
the gut and its microbiota
have emerged as major therapeutic targets.
Gut microbiota imbalance (or
dysbiosis), observed in many NCDs,
can worsen intestinal permeability and
trigger a systemic inflammatory response. Probiotics—defined as live
microorganisms that confer health benefits to the host—have been proposed as a
promising strategy to
restore microbiota balance, reinforce the gut barrier,
and positively modulate the gut-immune axis.
However, clinical study results have been
mixed. The effects vary depending on the probiotic strains used, the doses
administered, the duration of treatment, and patient profiles. Some studies
show improvement in inflammatory or antioxidant markers, while others show no
effect.
This variability makes it difficult to establish clear guidelines.
Therefore, this study was initiated to
clarify the actual impact of probiotic
supplementation on key biomarkers of inflammation and oxidative stress in
adults with NCDs.
Do probiotics really make a difference?
Eighteen randomized controlled trials, selected
according to PRISMA guidelines and the GRADE approach, were analyzed. Data were
synthesized using a random-effects model and presented as standardized mean
differences.
Results showed that
probiotic supplementation
significantly reduced several key biomarkers of inflammation and oxidative
stress. C-reactive protein (CRP) decreased notably, with a strong and
consistent effect across subpopulations, providing a high level of evidence.
Tumor necrosis factor-alpha (
TNF-α) was also reduced, although the effect was
more moderate and supported by a low level of evidence. Regarding oxidative
stress, malondialdehyde (
MDA)—a marker of lipid peroxidation—dropped sharply,
especially in patients with Alzheimer’s disease and those over 50.
Additionally, glutathione (GSH), a major antioxidant, increased significantly,
particularly in diabetic patients and young adults.
In contrast,
no significant effect was observed
on interleukin-6 (IL-6). Similarly,
probiotics had no notable impact on total
antioxidant capacity (TAC) or
nitric oxide (NO)
levels.
Positive effects were generally more pronounced
in studies with intervention durations of 12 weeks or longer, highlighting the
importance of allowing sufficient time for meaningful gut microbiota modulation
and sustained anti-inflammatory responses.
Read next: Postbiotics: Promising Results for Cardiovascular Health?
Microbes against inflammation: a successful
bet?
This meta-analysis suggests that
probiotic
supplementation may play a supportive role in reducing inflammation and
oxidative stress in patients with NCDs—particularly diabetes, multiple
sclerosis, and Alzheimer’s disease.
Probiotics positively affect certain
biomarkers (CRP, TNF-α, MDA, GSH), though their impact is limited on others
(IL-6, NO, TAC), likely due to individual differences, strain selection, or
treatment duration.
Modulating the gut microbiota via probiotics
appears to be a
promising avenue but requires refinement through longer-term,
standardized clinical trials. The lack of effect on some biomarkers highlights
the need to personalize probiotic approaches according to each patient’s
clinical and metabolic profile.
Read next: Youth and Supplements: Miracle or Trend?
